Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
UN

Unicorn Nest news

Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.

Source
1 2 3 … 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors:

Send